The Exciting Journey of Decentralized Clinical Trials and Other Emerging Therapies

In this Drug Digest video, our speaker will discuss emerging therapies and the impact of new technologies in the pipeline. Join the Drug Digest video to help prepare for decentralized clinical trials and other gene therapy advancements. Learn how an ecosystem of partners and understanding new technology relates to the targeted delivery space.

Register Free: https://www.pharmtech.com/pt_w/decentralized-clinical-trials

Event Overview:

Decentralized clinical trials (DCTs) have been a trending topic in more recent times, with FDA providing a draft guidance as of May 2023 that provides recommendations for sponsors, investigators, and other stakeholders regarding the implementation of DCTs to further advance medical research. If more trials were decentralized, it would allow some or all trial-related activities to take place at trial participants’ homes or other locations and increase diversity of participants in the clinical trials (1).

With additional steps like this taken towards DCTs, this would allow more support for the new emerging therapies and other devices that are in the pipeline and continue to gather the most accurate information for participants.

In this Drug Digest video, James Riddle, vice president of research services and strategic consulting at Advarra, will provide expert insights about emerging therapies and targeted delivery, including decentralized clinical trials, gene therapy, and new technologies in the pipeline.

• FDA. FDA Takes Additional Steps to Advance Decentralized Clinical Trials. May 2, 2023. https://www.fda.gov/news-events/press-announcements/fda-takes-additional-steps-advance-decentralized-clinical-trials

Key Learning Objectives:

• The ability to identify the most recent technologies so that participants know how to use them in decentralized clinical trials (DCTs)
• The ability to learn about improving enrollment and diversity within gene therapy trials
• Problem solving: ability to develop a plan for solving challenges that are associated with DCTs
• Awareness: ability to successfully pinpoint new advancements in technology and drug approvals to further improve patient outcomes

Who Should Attend:

• CDMOs
• Clinical trial investigators
• CROs
• Startup biotechs
• Clinicians administering gene therapy/cell therapy

Speaker:

James Riddle
Vice President of Research Services and Strategic Consulting
Advarra

Sponsors:

Register Free: https://www.pharmtech.com/pt_w/decentralized-clinical-trials